<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781716</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0-Sep 10, 2008</org_study_id>
    <nct_id>NCT00781716</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction (STEMI) and Analysis of Current Status of Emergency PCI Green Channel for STEMI Patients in China</brief_title>
  <acronym>CREST-MI</acronym>
  <official_title>Comparison of Safety and Efficacy of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction and Analysis of Current Status of Emergency PCI Green Channel for Patients With ST Elevation Myocardial Infarction in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the clinical effect of CYPHER® stent and ENDEAVOR® stent in patients
      with acute ST elevation myocardial infarction. It also aims to analyze the current status of
      emergency PCI green channel (time taken from door→ hospital→ PIC sign-off→ needle→ balloon)
      for patients with ST elevation myocardial infarction in China.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events defined as death, MI (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization (repeat PTCA or CABG)</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1020</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cypher Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cypher Sirolimus-Eluting Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor Zotarolimus-Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting coronary stent system</intervention_name>
    <description>Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System</description>
    <arm_group_label>Cypher Stent</arm_group_label>
    <arm_group_label>Endeavor Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be ≥18 years and ≤75 of age.

          2. Prolonged, continuous (≥ 30 min) chest pain despite nitrate and: (1) ST-segment
             elevation ≥ at least 2 leads, with reciprocal ST-segment elevation ≥ 0.05mv and
             precordial leads ST-segment elevation ≥ 0.01mv, or (2) newly developed left bundle
             branch block

          3. Symptoms ≥ 30 min and ≤12 hours

          4. The patient has consented to participate and has authorized the collection and release
             of his medical information by signing the &quot;Patient Informed Consent Form&quot;

          5. All lesions requiring interventions in one or more native coronary arteries are
             amendable for implantation of one or more Cypher® Sirolimus-Eluting Coronary Stent
             System or Endeavor® Zotarolimus-Eluting Coronary Stent

          6. The patient or guardian is willing and able to cooperate with study procedures and
             required follow up visits.

        Exclusion Criteria:

          1. Pregnant and breast-feeding female and female of childbearing potential, who possibly
             plan to become pregnant any time after enrollment into this study.

          2. Systemic (intravenous) Sirolimus use within 12 months.

          3. Patients with hypersensitivity or allergies to one of the drugs or components
             indicated in the Instructions for Use of either stents.

          4. History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), or will refuse blood transfusions.

          5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery
             within 2 months.

          6. Current platelet count &lt;100 x 10^9cells/L or Hgb &lt;10 g/dL.

          7. Fibrinolytic therapy for current MI treatment

          8. Previous coronary intervention on target vessel or post-CABG vessel disease

          9. Transplant patients

         10. Patients with EF&lt;25%

         11. Patients with cardiogenic shock; with a life expectancy shorter than 12 months

         12. Severe kidney dysfunction: Creatinine level ≥2.0mg/dL or dependence on dialysis.

         13. Severe hepatic dysfunction (AST and ALT ≥ 3 times upper normal reference values).

         14. The patient is currently, and during the CREST-MI Study, participating in another
             investigational device or drug study that clinically interferes with the CREST-MI
             study endpoints; or requires coronary angiography or other coronary artery imaging
             procedures. The patient may only be enrolled in the CREST-MI Study once.

         15. Severe tortuous or calcified vessel; stent can not or has difficulty to go through;
             blood vessel diameter is smaller than the minimum stent diameter available; patients
             unsuitable for stent implantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LeFeng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LeFeng Wang, MD</last_name>
    <phone>86-13601255020</phone>
    <email>CrestMI@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caihong Wang</last_name>
    <phone>86-13001980897</phone>
    <email>crest_mi@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital Heart Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LeFeng Wang, MD</last_name>
      <phone>86-13601255020</phone>
      <email>CrestMI@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>October 28, 2008</last_update_submitted>
  <last_update_submitted_qc>October 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. LeFeng Wang/Director of the Cath Lab</name_title>
    <organization>Beijing Chao Yang Hospital Heart Center</organization>
  </responsible_party>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>Drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

